Metoclopramide G.L. Pharma (Metoclopramide Hydrochloride)

Metoclopramide blocks dopamine D2 receptors in the brain’s chemoreceptor trigger zone, reducing the central signal for nausea. It also increases acetylcholine release in the gut, stimulating smooth‑muscle contraction and improving gastrointestinal motility.

The appropriate dose and duration are determined by the prescribing clinician based on the patient’s condition, age, renal function, and response to therapy. Dosing should follow the prescriber’s instructions and local regulatory guidelines.

Safety data for metoclopramide in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metoclopramide differs from many antiemetics by also having pro‑kinetic activity, which can be advantageous in gastroparesis. Compared with serotonin‑type 5‑HT3 antagonists, it may be less effective for severe chemotherapy nausea but offers the added benefit of enhancing gastric motility.

Metoclopramide G.L. Pharma should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations to maintain stability.

The product is supplied as an injectable solution for intravenous administration. It is typically given by a healthcare professional under aseptic conditions, either as a slow IV push or infusion, according to the prescriber’s instructions.

Serious risks include the development of tardive dyskinesia, neuroleptic malignant syndrome, and seizures. These events are rare but require immediate medical attention. Patients should be monitored for any abnormal movements or neurological changes during therapy.

Metoclopramide should be avoided in individuals with known hypersensitivity to the drug, those with pheochromocytoma, uncontrolled seizure disorders, or severe depression with suicidal tendencies. It is also contraindicated in patients taking MAO inhibitors within the past 14 days.